Skip to main content
NCBI home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1997 Jan-Feb;70(1):19–25.

Current Management Strategies in Acid-Related Disorders

Simon J Rune, Peter Bytzer
PMCID: PMC2589132

Abstract

Acid-related disorders include not only reflux esophagitis and peptic ulcer, but also a subset of patients with endoscopy-negative dyspepsia. The management strategy differs between these diseases and therefore a precise diagnosis is important. The unaided clinical diagnosis is of limited value in patients with pain or discomfort in the upper abdomen, and endoscopy is therefore an important and cost-effective diagnostic tool.

Duodenal ulcer is caused by an interplay between gastric acid and Helicobacter pylori. The treatment is aimed at rapid symptom relief and healing and at the same time eradication of H. pylori. At present the best choice is the combination of a proton pump inhibitor and two effective antimicrobial drugs, e.g., clarithromycin and metronidazole. The proton pump inhibitor has dual effect in this combination it provides optimal symptom relief and healing, and it increases the anti-H. pylori-effect of the antimicrobial drugs. The risk of reinfection varies geographically; in Europe it is around 1 percent per year, and cure of the infection provides long-term, maybe life-long, cure of the ulcer disease. Some gastric ulcers are not H. pylori-related and the treatment strategy therefore includes a diagnostic test for this infection. If positive, treatment is similar to that in duodenal ulcer, while H. pylori-negative gastric ulcer patients are treated with antisecretory drugs alone.

Reflux esophagitis correlates with the degree of acid exposure to the esophagus, and intensive acid inhibition is the most effective non-surgical therapy. In most cases the disease is chronic and needs continuous long-term therapy to prevent relapse. A staged reduction in dosage of the acid inhibitory drug may be attempted when the esophagitis is healed and the patient has become symptom free, but full dose therapy is often needed.

Patients with endoscopy-negative dyspepsia are a heterogenous group and a more precise identification of the cause of the symptoms is a prerequisite for rational treatment. Empiric treatment can be tried in patients without alarm symptoms like bleeding or a palpable abdominal mass, and often an acid inhibitory drug is used. A more precise identification of those patients who have acid-related symptoms is possible using placebo controlled single-subject trials with an effective acid inhibitory drug, but in daily routine these drugs are simply given for a short period of time, and in case symptomatic relief is observed, the symptoms may be regarded as being acid-related and treated accordingly.

Full text

PDF
19

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bate C. M., Griffin S. M., Keeling P. W., Axon A. T., Dronfield M. W., Chapman R. W., O'Donoghue D., Calam J., Crowe J., Mountfords R. A. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther. 1996 Aug;10(4):547–555. doi: 10.1046/j.1365-2036.1996.44186000.x. [DOI] [PubMed] [Google Scholar]
  2. Bytzer P. Endoscopic follow-up study of gastric ulcer to detect malignancy: is it worthwhile? Scand J Gastroenterol. 1991 Nov;26(11):1193–1199. doi: 10.3109/00365529108998613. [DOI] [PubMed] [Google Scholar]
  3. Bytzer P., Hansen J. M., Havelund T., Malchow-Møller A., Schaffalitzky de Muckadell O. B. Predicting endoscopic diagnosis in the dyspeptic patient: the value of clinical judgement. Eur J Gastroenterol Hepatol. 1996 Apr;8(4):359–363. doi: 10.1097/00042737-199604000-00014. [DOI] [PubMed] [Google Scholar]
  4. Bytzer P., Hansen J. M., Schaffalitzky de Muckadell O. B. Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet. 1994 Apr 2;343(8901):811–816. doi: 10.1016/s0140-6736(94)92023-0. [DOI] [PubMed] [Google Scholar]
  5. Ching C. K., Lam S. K. A comparison of two prostaglandin analogues (enprostil vs misoprostol) in the treatment of acute duodenal ulcer disease. J Gastroenterol. 1995 Oct;30(5):607–614. doi: 10.1007/BF02367786. [DOI] [PubMed] [Google Scholar]
  6. Fendrick A. M., Chernew M. E., Hirth R. A., Bloom B. S. Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med. 1995 Aug 15;123(4):260–268. doi: 10.7326/0003-4819-123-4-199508150-00003. [DOI] [PubMed] [Google Scholar]
  7. Forbes G. M., Glaser M. E., Cullen D. J., Warren J. R., Christiansen K. J., Marshall B. J., Collins B. J. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet. 1994 Jan 29;343(8892):258–260. doi: 10.1016/s0140-6736(94)91111-8. [DOI] [PubMed] [Google Scholar]
  8. Hallissey M. T., Allum W. H., Jewkes A. J., Ellis D. J., Fielding J. W. Early detection of gastric cancer. BMJ. 1990 Sep 15;301(6751):513–515. doi: 10.1136/bmj.301.6751.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hosking S. W., Ling T. K., Chung S. C., Yung M. Y., Cheng A. F., Sung J. J., Li A. K. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet. 1994 Feb 26;343(8896):508–510. doi: 10.1016/s0140-6736(94)91460-5. [DOI] [PubMed] [Google Scholar]
  10. Johannessen T., Fjøsne U., Kleveland P. M., Halvorsen T., Kristensen P., Løge I., Hafstad P. E., Sandbakken P., Petersen H. Cimetidine responders in non-ulcer dyspepsia. Scand J Gastroenterol. 1988 Apr;23(3):327–336. doi: 10.3109/00365528809093874. [DOI] [PubMed] [Google Scholar]
  11. Lauritsen K., Laursen L. S., Havelund T., Bytzer P., Svendsen L. B., Rask-Madsen J. Enprostil and ranitidine in duodenal ulcer healing: double blind comparative trial. Br Med J (Clin Res Ed) 1986 Mar 29;292(6524):864–866. doi: 10.1136/bmj.292.6524.864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mattioli S., Pilotti V., Spangaro M., Grigioni W. F., Zannoli R., Felice V., Conci A., Gozzetti G. Reliability of 24-hour home esophageal pH monitoring in diagnosis of gastroesophageal reflux. Dig Dis Sci. 1989 Jan;34(1):71–78. doi: 10.1007/BF01536157. [DOI] [PubMed] [Google Scholar]
  13. McDougall N. I., Johnston B. T., Kee F., Collins J. S., McFarland R. J., Love A. H. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut. 1996 Apr;38(4):481–486. doi: 10.1136/gut.38.4.481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Moayyedi P., Sahay P., Tompkins D. S., Axon A. T. Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol. 1995 Sep;7(9):835–840. [PubMed] [Google Scholar]
  15. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA. 1994 Jul 6;272(1):65–69. [PubMed] [Google Scholar]
  16. Nebel O. T., Fornes M. F., Castell D. O. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis. 1976 Nov;21(11):953–956. doi: 10.1007/BF01071906. [DOI] [PubMed] [Google Scholar]
  17. Patel P., Khulusi S., Mendall M. A., Lloyd R., Jazrawi R., Maxwell J. D., Northfield T. C. Prospective screening of dyspeptic patients by Helicobacter pylori serology. Lancet. 1995 Nov 18;346(8986):1315–1318. doi: 10.1016/s0140-6736(95)92340-3. [DOI] [PubMed] [Google Scholar]
  18. Peura D. A. Helicobacter pylori: a diagnostic dilemma and a dilemma of diagnosis. Gastroenterology. 1995 Jul;109(1):313–315. doi: 10.1016/0016-5085(95)90299-6. [DOI] [PubMed] [Google Scholar]
  19. Rabeneck L. Managing dyspepsia: is prompt endoscopy the way to go? Gastroenterology. 1995 Apr;108(4):1324–1326. doi: 10.1016/0016-5085(95)90243-0. [DOI] [PubMed] [Google Scholar]
  20. Ruth M., Månsson I., Sandberg N. The prevalence of symptoms suggestive of esophageal disorders. Scand J Gastroenterol. 1991 Jan;26(1):73–81. doi: 10.3109/00365529108996486. [DOI] [PubMed] [Google Scholar]
  21. Shi G., Bruley des Varannes S., Scarpignato C., Le Rhun M., Galmiche J. P. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut. 1995 Oct;37(4):457–464. doi: 10.1136/gut.37.4.457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Silverstein M. D., Petterson T., Talley N. J. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology. 1996 Jan;110(1):72–83. doi: 10.1053/gast.1996.v110.pm8536890. [DOI] [PubMed] [Google Scholar]
  23. Trimble K. C., Douglas S., Pryde A., Heading R. C. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux. Dig Dis Sci. 1995 May;40(5):1098–1104. doi: 10.1007/BF02064206. [DOI] [PubMed] [Google Scholar]
  24. Trimble K. C., Pryde A., Heading R. C. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut. 1995 Jul;37(1):7–12. doi: 10.1136/gut.37.1.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Tytgat G. N., Anker Hansen O. J., Carling L., de Groot G. H., Geldof H., Glise H., Efskind P., Elsborg L., Karvonen A. L., Ohlin B. Effect of cisapride on relapse of reflux oesophagitis, healed with an antisecretory drug. Scand J Gastroenterol. 1992;27(3):175–183. doi: 10.3109/00365529208999945. [DOI] [PubMed] [Google Scholar]
  26. Tytgat G. N., Janssens J., Reynolds J. C., Wienbeck M. Update on the pathophysiology and management of gastro-oesophageal reflux disease: the role of prokinetic therapy. Eur J Gastroenterol Hepatol. 1996 Jun;8(6):603–611. doi: 10.1097/00042737-199606000-00020. [DOI] [PubMed] [Google Scholar]
  27. Vigneri S., Termini R., Leandro G., Badalamenti S., Pantalena M., Savarino V., Di Mario F., Battaglia G., Mela G. S., Pilotto A. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995 Oct 26;333(17):1106–1110. doi: 10.1056/NEJM199510263331703. [DOI] [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES